Response to: ‘JAK inhibitors as promising agents for refractory Takayasu arteritis’ by Watanabe

We thank Watanabe for his interest in our case report showing that tocilizumab, a Janus kinase (JAK) inhibitor, successfully induced a remission of Takayasu arteritis (TAK) complicated by ulcerative colitis (UC) and for providing some meaningful comments to supplement our discussion. Watanabe wonders if JAK inhibitors can be effective in TAK patients without UC. In addition, he is concerned that types of JAK inhibitors may affect the efficiency in treating TAK. We agree that the issues should be evaluated in a large-scale case series and clinical study. According to a limited number of case reports, JAK inhibitors were effective in TAK regardless of coexisting UC and types of JAK inhibitors. Sato et al reported a similar case of TAK with UC successfully treated with tocilizumab (JAK1/JAK3 inhibitor). On the other hand, Régnier et al reported that ruxolitinib or baricitinib (JAK1/JAK2 inhibitors) clinically improved TAK without UC in three patients. They also demonstrated that the improvement was along with decrease of Th1/Th17-related cytokines and correction of effector/regulatory T-cell imbalance. However, as suggested by Watanabe, JAK inhibitors could modulate innate immunity composed of macrophages and natural killer cells in TAK.

For the management of refractory TAK, EULAR recommends considering tumour necrosis factor (TNF) inhibitor or tocilizumab, although the evidence for TNF inhibitor depends on only open-label studies, and a randomised controlled trial of tocilizumab failed to achieve its primary endpoint. Tocilizumab rapidly normalises IL-6-driven serum inflammatory markers despite sustained vessel inflammation. It can be confusing when the disease activity of TAK is correctly assessed. Thus, additional treatment options with clear evidence have been desired for TAK. To conclude, we believe that further studies should be conducted in refractory TAK for evaluating the efficacy and safety of JAK inhibitors as a promising agent.

Shun Tanimura, Hiroyuki Nakamura, Tetsuya Horita

Internal Medicine, Tomakomai City Hospital, Tomakomai, Hokkaido, Japan

Correspondence to Dr Tetsuya Horita, Internal Medicine, Tomakomai City Hospital, Tomakomai 053-8567, Japan; thorita@med.hokudai.ac.jp

Contributors ST and HN wrote the manuscript. TH contributed to the discussion and edited the manuscript. All authors read and approved the final manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite Tanimura S, Nakamura H, Horita T. Ann Rheum Dis Epub ahead of print: [please include Day Month Year]. doi:10.1136/annrheumdis-2020-217680

Accepted 23 April 2020

Received 20 April 2020

http://dx.doi.org/10.1136/annrheumdis-2020-217577

Ann Rheum Dis 2020:0.1. doi:10.1136/annrheumdis-2020-217680

ORCID iDs

Shun Tanimura http://orcid.org/0000-0002-9640-2527

Tetsuya Horita http://orcid.org/0000-0003-2332-3841

REFERENCES


